Agios Pharmaceuticals, Inc.
A biopharmaceutical company in Cambridge, Massachusetts, that develops treatments for rare blood disorders by targeting cellular metabolism. Its main product, PYRUKYND (mitapivat), is an oral medicine for hemolytic anemia in adults with pyruvate kinase deficiency. Founded in 2008 by three cancer researchers, the company takes its name from the Greek word for "holy" — and sold its cancer business in 2021 to focus on rare genetic diseases.
Bought 1.00M
Bought 1.88M
Bought 228.6K
Granted 1.07M · Bought 8.1K · Sold 965.8K
Sold 172.4K
Granted 351.8K · Sold 167.2K
Granted 181.6K · Bought 40.3K · Sold 45.1K
Granted 432.3K · Sold 341.2K
Granted 400.7K · Sold 331.0K
Sold 419.0K
Bought 55.6K
Granted 131.3K · Sold 51.0K
Granted 80.3K · Sold 27.7K
Granted 101.7K · Sold 54.1K
Granted 72.2K · Sold 25.3K
Granted 6.5K · Bought 14.7K
Granted 35.1K
Granted 32.2K
Granted 22.2K · Bought 200 · Sold 2.4K
Granted 19.8K
Granted 24.3K
Granted 42.1K · Sold 24.4K
Granted 242.3K · Sold 217.5K
Granted 35.2K · Sold 20.0K
Granted 15.2K
Granted 62.8K · Sold 46.8K
Granted 10.9K
Granted 8.9K
Granted 16.2K · Sold 5.9K
Granted 11.3K
Granted 10.3K · Sold 6.2K
Granted 6.5K
Granted 6.5K
Granted 2.0K
Granted 31.2K · Sold 32.2K
Granted 147.4K · Sold 142.5K
Granted 15.3K · Sold 13.2K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Celgene Corp /De/ +2 co-filers10% owner · 4 transactions | — | 7.61Mas of Apr 2014 | — | 1.00M | — |
| Celgene Corp /De/ +3 co-filers10% owner · 3 transactions | — | 7.12Mas of Nov 2019 | — | 1.88M | — |
| Celgene European Investment Co LLC10% owner · 1 transaction | — | 5.24Mas of Dec 2014 | — | 228.6K | — |
| Arch Venture Fund VII LP +4 co-filers10% owner · 3 transactions | — | 3.09Mas of Feb 2015 | — | — | — |
| Afeyan Noubar +3 co-filers10% owner · 2 transactions | — | 1.93Mas of Jun 2014 | — | — | — |
| Starr Kevin PDirector, 10% owner · 13 transactions | — | 944.6Kas of Feb 2015 | — | — | — |
| Schenkein David PDirector · 175 transactions | — | 476.1Kas of Jun 2024 | 1.07M | 8.1K | 965.8K |
| Cantley Lewis Clayton Jr.Director · 144 transactions | — | 436.6Kas of Dec 2017 | — | — | 172.4K |
| Goff BrianChief Executive Officer, Director · 38 transactions | — | 191.1K | 351.8K | — | 167.2K |
| Fouse Jacqualyn ADirector · 27 transactions | — | 154.2K | 181.6K | 40.3K | 45.1K |
| Biller ScottChief Scientific Officer · 151 transactions | — | 146.1Kas of Jun 2019 | 432.3K | — | 341.2K |
| Higgons John DuncanChief Operating Officer · 66 transactions | — | 118.9Kas of Jan 2016 | 400.7K | — | 331.0K |
| Nelsen RobertDirector · 30 transactions | — | 109.2Kas of Mar 2017 | — | — | 419.0K |
| Tessier-Lavigne MarcDirector · 1 transaction | — | 101.0Kas of Jul 2013 | — | 55.6K | — |
| Gheuens SarahChief Medical Officer · 57 transactions | — | 80.3K | 131.3K | — | 51.0K |
| Jones CeciliaChief Financial Officer · 30 transactions | — | 55.0K | 80.3K | — | 27.7K |
| Burns James WilliamChief Legal Officer · 50 transactions | — | 49.3K | 101.7K | — | 54.1K |
| Milanova TsvetaChief Commercial Officer · 22 transactions | — | 46.8K | 72.2K | — | 25.3K |
| Maraganore JohnDirector · 16 transactions | — | 28.5Kas of Sep 2022 | 6.5K | 14.7K | — |
| Hirsch AndrewChief Financial Officer · 12 transactions | — | 26.2Kas of Apr 2020 | 35.1K | — | — |
| Biller JonathanChief Financial Officer · 10 transactions | — | 23.0Kas of Feb 2022 | 32.2K | — | — |
| Scadden DavidDirector · 21 transactions | — | 20.4K | 22.2K | 200 | 2.4K |
| Ho MaykinDirector · 8 transactions | — | 19.8K | 19.8K | — | — |
| Car BruceChief Scientific Officer · 10 transactions | — | 16.8Kas of Feb 2022 | 24.3K | — | — |
| Hoerter Steven L.Chief Commercial Officer · 22 transactions | — | 15.9Kas of Mar 2019 | 42.1K | — | 24.4K |
| Bowden ChristopherChief Medical Officer · 82 transactions | — | 15.5Kas of Jun 2021 | 242.3K | — | 217.5K |
| Ballal Rahul D.Director · 13 transactions | — | 15.2K | 35.2K | — | 20.0K |
| Smith CynthiaDirector · 6 transactions | — | 15.2K | 15.2K | — | — |
| Foster-Cheek Kaye IDirector · 22 transactions | — | 12.5K | 62.8K | — | 46.8K |
| Capello Jeffrey DDirector · 5 transactions | — | 10.9K | 10.9K | — | — |
| Owen Adams CatherineDirector · 4 transactions | — | 10.9K | 8.9K | — | — |
| Viswanadhan KrishnanChief Corp Dev & Strategy · 4 transactions | — | 10.3K | 16.2K | — | 5.9K |
| Poddar RichaChief Commercial Officer · 9 transactions | — | 8.5Kas of Oct 2022 | 11.3K | — | — |
| Miles DarrinChief Commercial Officer · 8 transactions | — | 7.2Kas of May 2021 | 10.3K | — | 6.2K |
| Clark Ian TDirector · 4 transactions | — | 6.5Kas of May 2022 | 6.5K | — | — |
| Clancy Paul JDirector · 4 transactions | — | 6.5Kas of May 2022 | 6.5K | — | — |
| Cole Douglas G.Director · 2 transactions | — | 2.8Kas of Aug 2016 | — | — | — |
| Owen Catherine E.Director · 1 transaction | — | 2.0Kas of Jun 2024 | 2.0K | — | — |
| Washburn Theodore James Jr.Principal Accounting Officer · 47 transactions | — | 868 | 31.2K | — | 32.2K |
| Goddard GlennSenior Vice President, Finance · 64 transactions | — | 0as of Sep 2015 | 147.4K | — | 142.5K |
| Alenson CarmanPrincipal Accounting Officer · 30 transactions | — | 0as of Jun 2021 | 15.3K | — | 13.2K |
| Third Rock Ventures LP +2 co-filers10% owner · 10 transactions | — | 0as of Feb 2015 | — | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +118.4K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.